REPURPOSING SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS FOR GEROTHERAPY

Abstract

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are drugs used to treat T2DM, offering benefits such as reduced HbA1c, weight loss, and improved insulin sensitivity/β-cell function. Additionally, they provide significant cardio-renal benefits, although the exact mechanisms are not fully understood.